Regulatory and competitive uncertainties in the marketplace lead many life sciences companies to enter into collaborative arrangements with other companies to develop new drugs or medical devices. These arrangements allow for the leverage of expertise that may not have been available in-house – such as a pharmaceutical company that sees promising new science from a biotech startup – while also sharing in the costs and risks of new product development.
{iframe}https://www.bizjournals.com/boston/news/2018/06/06/life-sciences-companies-could-see-changes-in.html{/iframe}